Teysuno is a cancer medicine. It belongs to a group of cancer medicines called fluoropyrimidines and is used to treat advanced gastric (stomach) cancer together with cisplatin (another cancer medicine). It is also used to treat metastatic colorectal cancer (cancer of the colon and rectum that has spread elsewhere in the body) in patients who can no longer be treated with other fluoropyrimidines because of unacceptable side effects. For this it may be used alone or with the cancer medicines oxaliplatin or irinotecan, with or without another medicine, bevacizumab. Teysuno contains the active substances tegafur, gimeracil and oteracil.
Therapeutic Indication
### Therapeutic indication Teysuno is indicated in adults: \- for the treatment of advanced gastric cancer when given in combination with cisplatin (see section 5.1). \- as monotherapy or in combination with oxaliplatin or irinotecan, with or without bevacizumab, for the treatment of patients with metastatic colorectal cancer for whom it is not possible to continue treatment with another fluoropyrimidine due to hand-foot syndrome or cardiovascular toxicity that developed in the adjuvant or metastatic setting.
Therapeutic Area (MeSH)
ATC Code
L01BC53
ATC Item
tegafur, combinations
Pharmacotherapeutic Group
Antineoplastic agents
Active Substance (Summary)
INN / Common Names
EMA Name
Teysuno
Medicine Name
Teysuno
Aliases
N/ANo risk management plan link.
